Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis.

ABSTRACT:

Background

The efficacy of nirmatrelvir plus ritonavir (NMV-r) for vaccinated COVID-19 patients at high risk of progression is not adequately recognised. To address this gap, we conducted a systematic review and meta-analysis of current literature.

Methods

We searched PubMed, Web of Science, Embase, Cochrane Library, and medRxiv for articles published up to 8 January 2023 on NMV-r in outpatients. At least two researchers screened articles, extracted data, and assessed the quality of selected studies. We evaluated the results via risk ratios (RRs) with 95% confidence intervals (CIs) and tested for heterogeneity using I² statistics.

Results

We included seven observational cohort studies comprising 224 238 vaccinated patients. According to our meta-analysis, N

SUBMITTER: Li H 

PROVIDER: S-EPMC10357131 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature